Diffusion Pharmaceuticals appoints Jill Davidson to board under settlement agreement

CervoMed Inc.

Jill Davidson appointed as director effective July 26, 2023, expanding board to seven members.
Appointment made pursuant to December 2022 Settlement Agreement with LifeSci Group.
Davidson designated as one of two Company Designees for post-merger board if EIP Pharma merger closes.
Term expires at 2023 annual meeting or when LifeSci Group's net long position falls below 96,976 shares.
Davidson will receive standard non-employee director compensation and enter indemnification agreement.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jill Davidson

director

CRVO · CervoMed Inc.

Effective: 2023-07-26
Filed: July 31, 2023, 7:59 PM ET

Effective July 26, 2023, the Board of Directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) appointed Jill Davidson as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jill Davidson was appointed as director at CervoMed Inc..

Action: appointed
Role: director

Exact text from the filing

Effective July 26, 2023, the Board of Directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) appointed Jill Davidson as a director of the Company.

View on SEC.gov

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-021201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.